According to West Point Pharmaceutical's announcement, Hengqin Dingdian, a shareholder holding more than 5% of the shares, and its co-actor, Zhuhai Hengqin Runhuiyi, reduced their holdings by a total of 1,115,700 shares through centralized bidding and bulk transactions from April 17 to July 16, 2026, accounting for 1.4779% of the company's total share capital. After the holdings were reduced, the two held a total of 6.0798.97 million shares, accounting for 8.0534%, and are still shareholders holding more than 5% of the company's shares. This reduction in holdings has not led to a change in the company's control and will not have an impact on corporate governance and operations.

According to West Point Pharmaceutical's announcement, Hengqin Dingdian, a shareholder holding more than 5% of the shares, and its co-actor, Zhuhai Hengqin Runhuiyi, reduced their holdings by a total of 1,115,700 shares through centralized bidding and bulk transactions from April 17 to July 16, 2026, accounting for 1.4779% of the company's total share capital. After the holdings were reduced, the two held a total of 6.0798.97 million shares, accounting for 8.0534%, and are still shareholders holding more than 5% of the company's shares. This reduction in holdings has not led to a change in the company's control and will not have an impact on corporate governance and operations.